Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence - Abstract

OBJECTIVE: To establish 18 fluorocholine-positron emission tomography/computed tomography (F-PET/CT) performances for the detection of local recurrence in a population of patients with biochemical failure after primary curative treatment for localized prostate carcinoma.

MATERIAL AND METHOD: From February 2011 to February 2014, 55 patients underwent a F-PET/CT for biochemical relapse after primary radical therapy for prostate cancer localized or locally advanced. Primary therapies for prostate cancer were 19 radical prostatectomy, 18 radiotherapy, 13 radiotherapy with hormonal treatment, 3 brachytherapy. The median age was 65 years (50-79). The initial staging was 17 T1, 23 T2 and 15 T3, 52 were N0 and N1 3. The median PSA was 12 (3-127). The Gleason score was less than 7, equal to 7 and greater than 7 at 21, 25 and 9 patients respectively. The average time to recurrence was 69.5 months (8-147) with a median PSA of 2.9ng/mL (0.48-41).

RESULTS: In 42 cases, F-PET/CT showed uptake, suggesting a recurrence, metastatic (6), nodal (26) or local isolated (10). The focal uptake in PET commissioned in 5 cases prostate biopsy, confirming the histological recurrence of prostate cancer in 4 cases. Among the 10 patients with isolated local recurrence, 8 underwent salvage radiotherapy. Of the 13 cases where the (F-PET/CT) showed no recurrence, 7 multiparametric MRI were performed. The MRI showed a local recurrence in 3 patients, the diagnoses were confirmed with prostate biopsy for two of them.

CONCLUSION: In our study, for the patients with biochemical relapse of prostate adenocarcinoma localized or locally advanced, (F-PET/CT) was able to detect local recurrence isolated in nearly half the cases but did not show sufficient sensitivity to exclude recurrence local if negative. It does not replace MRI or additional prostate biopsy.

Written by:
Poncet D, Arnoux V, Descotes JL, Rambeaud JJ, Verry C, Terrier N, Boillot B, Dubreuil J, Lanchon C, Carnicelli D, Fiard G, Long JA.   Are you the author?
Service d'urologie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France; Service de radiothérapie, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France; Service de médecine nucléaire, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France.  

Reference: Prog Urol. 2015 Mar 4. pii: S1166-7087(15)00034-2.
doi: 10.1016/j.purol.2015.01.018


PubMed Abstract
PMID: 25748788

Article in French.

UroToday.com Prostate Cancer Section